Lexicon Pharmaceuticals, Inc.
LXRX
$1.62
$0.010.62%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 49.80M | 70.86M | 58.43M | 31.21M | 31.08M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 49.80M | 70.86M | 58.43M | 31.21M | 31.08M |
| Cost of Revenue | -21.29M | -29.58M | -22.50M | -22.31M | -22.29M |
| Gross Profit | 71.10M | 100.45M | 80.93M | 53.52M | 53.37M |
| SG&A Expenses | 37.32M | 60.82M | 92.81M | 122.65M | 143.10M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 98.71M | 136.63M | 175.71M | 207.58M | 227.10M |
| Operating Income | -48.91M | -65.77M | -117.27M | -176.36M | -196.02M |
| Income Before Tax | -50.34M | -68.58M | -120.62M | -177.30M | -200.40M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -50.34 | -68.58 | -120.62 | -177.30 | -200.40 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -50.34M | -68.58M | -120.62M | -177.30M | -200.40M |
| EBIT | -48.91M | -65.77M | -117.27M | -176.36M | -196.02M |
| EBITDA | -48.29M | -65.14M | -116.67M | -175.80M | -195.48M |
| EPS Basic | -0.14 | -0.19 | -0.33 | -0.51 | -0.64 |
| Normalized Basic EPS | -0.09 | -0.12 | -0.21 | -0.32 | -0.40 |
| EPS Diluted | -0.14 | -0.19 | -0.33 | -0.51 | -0.64 |
| Normalized Diluted EPS | -0.09 | -0.12 | -0.21 | -0.32 | -0.40 |
| Average Basic Shares Outstanding | 1.45B | 1.45B | 1.45B | 1.40B | 1.28B |
| Average Diluted Shares Outstanding | 1.45B | 1.45B | 1.45B | 1.40B | 1.28B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |